Essential bromodomain *TcBDF2* as a drug target against Chagas disease

Alejandro Pezza^{#1}, Luis E Tavernelli^{#1}, Victoria L Alonso^{1,2}, Virginia Perdomo², Raquel Gabarro³, Rab Prinjha⁵, Elvio Rodríguez Araya^{1,2}, Inmaculada Rioja⁵, Roberto Docampo⁴, Felix Calderón³, Julio Martín^{3†}, Esteban Serra^{1,2*}.

¹ Instituto de Biología Molecular y Celular de Rosario, CONICET. Rosario, Argentina.

² Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario. Rosario, Argentina.

³ GlaxoSmithKline Global Health, Tres Cantos, 28760, Madrid, Spain.

⁴ Department of Cellular Biology and Center for Tropical and Global Emerging Diseases, University of Georgia, Athens 30602, USA.

⁵ Immunology Research Unit, Research, R&D GlaxoSmithKline, Gunnels Wood Road, Stevenage, Herts, SG1 2NY, UK.

† Current address: Sciengement Lab Consulting, 28750 San Agustin del Guadalix, Spain.

These Authors contributed equally to the manuscript.

*Address correspondence to Esteban Serra, serra@ibr-conicet.gov.ar.

Abstract

Trypanosoma cruzi is a unicellular parasite that causes Chagas disease, which is endemic in the American continent but also worldwide distributed by migratory movements. A striking feature of trypanosomatids is the polycistronic transcription associated with post-transcriptional mechanisms that regulate the levels of translatable mRNA. In this context, epigenetic regulatory mechanisms have been revealed of great importance, since they are the only ones that would control the access of RNA polymerases to chromatin. Bromodomains are epigenetic protein readers that recognize and specifically bind to acetylated lysine residues, mostly at histone proteins. There are seven coding sequences for BD-containing proteins in trypanosomatids, named *TcBDF1* to *TcBDF7*, and a putative new protein-containing a bromodomain that was recently described. Using the Tet regulated overexpression plasmid p*TcINDEX*-GW and CRISPR/Cas9 genome editing we were able to demonstrate the essentiality of *TcBDF2* in *T. cruzi*. This bromodomain is located in the nucleus, through a bipartite nuclear localization signal. *TcBDF2* was shown to be important for host cell invasion, amastigote replication, and differentiation from amastigotes to trypomastigotes. Overexpression of *TcBDF2* diminished epimastigote replication. Also, some processes involved in pathogenesis were altered in these parasites, such as infection of mammalian cells, replication of amastigotes, and the number of trypomastigotes released from host cells. In *in vitro* studies, *TcBDF2* was also able to bind inhibitors showing a specificity profile different from that of the previously characterized *TcBDF3*. These results, point to *TcBDF2* as a druggable target against *T. cruzi*.

Introduction

The World Health Organization (WHO) estimates the prevalence of Chagas' disease (or American Trypanosomiasis) in about 7 million cases, of which between 20 to 30% develop severe clinical manifestations¹². Originally confined to Latin America, migration is spreading the disease to non-endemic countries, where can be transmitted by blood transfusion, organ transplantation, and from infected women to their offspring during pregnancy. There are two active compounds (nifurtimox and benznidazole) that are used in the treatment of the acute phase of the disease. Both have strong side effects and their efficacy in the chronic phase is controversial. This situation has made evident the need to find new trypanocidal compounds that can be used as therapeutic alternatives for all stages of the disease³.

In Trypanosomatids, genes are organized and transcribed in a quite unusual polycistronic fashion. The primary long transcripts are processed to mature translatable mRNAs by adding a 5' capped common short RNA sequence by *trans*-splicing and a 3 poly-A tail⁴. The final gene expression levels are regulated by several post-transcriptional mechanisms, which are not yet completely understood⁵. In parallel, transcription appears to be controlled by several proteins, histones, and non-histones, which compose and regulate chromatin accessibility and are now starting to be identified⁶⁻⁸. Chromatin structure can be altered by post-translational modifications in the N-terminal tails of histones, by the substitution of one or more histones by their variants, or by combinations of these events⁹. These conformational changes regulate not only the ability of chromatin to be transcribed but also other DNA-related processes such as recombination, replication, repair, and chromosomal segregation during metaphase¹⁰.

Regarding post-translational modifications of histones, acetylated H3 and H4 have been mapped to the beginning of the polycistronic units, considered to be the RNA Polymerase II (RNAPII) transcription initiation sites in *Trypanosoma cruzi*, *Trypanosoma brucei*, and *Leishmania* spp, suggesting a conserved localization for canonical histones among the TriTryps¹¹⁻¹³. Histone variants have been also mapped in *T. brucei* and *Leishmania major*¹⁴⁻¹⁷. H2A.Z and H2B.V, usually associated with less stable nucleosomes, were found to be enriched at the putative RNA Pol II transcription start regions (TSRs), while histone variants H3V and H4V (that seems to be specific of *T. brucei*) were found enriched at the end of the polycistronic transcription units, suggesting a role in transcription termination. Acetylated H2A.Z at the TSRs was also associated with the transcription level of the whole gene tandems (Kraus et al, 2020). More recently, H2B.V was found at the beginning of gene clusters in divergent strand switch regions in *T. cruzi*, as well as in some tDNA loci¹⁸. Interestingly, TcH2B.V was also found between conserved and disrupted genome compartments. In these zones, multigenic families of surface proteins like *trans*-sialidases, MASP, and mucins, are concentrated¹⁹.

Bromodomains (BD) form a family of "modified reader" proteins that recognize the acetylation marks on histones working as a scaffold for the assembly of macromolecular complexes that alter the accessibility to chromatin. However, new and more complex functions for this protein family were recently proposed²⁰. Proteins containing BDs are now considered druggable and BD

inhibitors are currently assayed in a myriad of pathologies such as cancer or inflammatory diseases among others^{20–23}. Parasite bromodomains are also proposed as drug targets, and a small number of inhibitors have been previously tested in *T. cruzi*, *T. brucei*, *Plasmodium falciparum*, and *Toxoplasma gondii*^{15,24–30}.

Our laboratory has been interested in the characterization of bromodomain factors from *Trypanosoma cruzi* (TcBDFs). According to the TriTrypDB (<http://tritrypdb.org/tritrypdb/>), there are seven coding sequences for BD-containing proteins in trypanosomatids, named TcBDF1 to TcBDF7. An eighth putative bromodomain factor recently identified in *Leishmania spp* has an orthologue in *T. cruzi*⁸. Even though a few TcBDFs have recognizable additional domains the architecture of these proteins seems to be simpler than those of BD-containing proteins from fungi and animals, and none contains histone acetyltransferase (HAT) domains, as occurs in at least one bromodomain-containing protein from almost all eukaryotic cells including many protists.

The BDs from TriTryp BDFs share limited identity among them as well as with any other eukaryotic or bacterial BDs³¹. The inner core is different in each domain and only a limited number of the hyper conserved amino acids are present, also the hydrophobic pocket is mostly constituted by non-identical amino acids with conserved hydrophobicity. This huge divergence of BDs from trypanosomatids is not surprising considering the highly atypical nuclear biology of these early branched protists. Despite this, the solved crystallographic structure of TcBD2 and TcBD5.1 showed the typical four alpha helices, each separated by two loops that form the hydrophobic acetyl lysine-binding pocket (PDB ID: 6NP7, 6NEY). Moreover, new reliable structures were generated by AlphaFold 2, showing the typical fold of the domain for all the *T. cruzi* bromodomains (<https://alphafold.ebi.ac.uk/>). Surprisingly, TcBDF7 one of the most conserved proteins of the family shows a typical BD folding but the hydrophobic pocket seems to be buried in the predicted structure.

We have previously characterized TcBDF1, TcBDF2, and TcBDF3 from *T. cruzi*. Interestingly, we found that TcBDF1 and TcBDF3 are mainly localized to the cytosol of *T. cruzi* cells. TcBDF1 was found in the glycosome, it is developmentally regulated throughout the *T. cruzi* life cycle, and its importance for parasite fitness has been well established³². TcBDF3, which was found to be associated with acetylated α -tubulin at the subpellicular corset and flagella, was found necessary for the differentiation of both epimastigotes and intracellular amastigotes to trypomastigotes³³. In addition, complete knockouts for *Tcbdf1* and *Tcbdf3* could not be obtained by CRISPR/Cas9 genome editing (unpublished results). We also described two compounds that bind to TcBD3 *in vitro* and also have trypanocidal activity^{24–26}. TcBDF2 was the first BD to be described in trypanosomatids and it is expressed throughout the whole life cycle of the parasite, and located in discrete regions of the nucleus. We also showed that it can interact with histone H4 through acetylated K10 and K14 and we also detected interaction with H2 by far-western blot analysis³⁴. Recently, TcBDF2 was found to be associated with H2B.V in pull-down assays and it was also shown to interact *in vitro* with H2B.V, H2B, and H4¹⁸.

In contrast to *T. cruzi* BDFs, all BD-containing proteins from *T. brucei* were described to be nuclear, and it has been proposed that many of them are essential for the maintenance of the

bloodstream form of this parasite^{35,36}. However, a recent study showed that *TbBDF4* has a bipartite nuclear-cytosolic localization⁷. Even though a genome-wide RNA interference viability screen showed that *TbBDF2* was not essential, it was found essential in another assay³⁶. Very recently, Jones *et al* (ref) showed that five of the seven BDFs, among them BDF2, are essential for *Leishmania mexicana* promastigotes.

There are also some discrepancies about the sites of interaction of *TbBDF2* within the genome. Early studies did not find *TbBDF2* enriched at RNAPII TSRs^{12,36}. However, *TbBDF2* was found later to be bound to the hyperacetylated form of the variant histone H2A.Z at the TSRs and placed also at the nucleolus¹⁵. Later, in a systematic study of *T. brucei* potential chromatin factors, *TbBDF2* was found broadly enriched at TSRs, following the direction of RNAPII transcription for 5-10 kb together with H2A.Z and H2B.V⁷. In this report *TbBDF2* was shown to immunoprecipitate with many proteins with recognizable HDAC, helicase, HIT, and CW-type zinc fingers and histone binding domains, among others. Based on a global interpretation of all their immunoprecipitation results, Staneva *et. al.* (ref) proposed that *TbBDF2* could be included in at least two complexes: (1) a chromatin remodeling complex related to SWR1, which is responsible for the incorporation of H2A.Z into chromatin in other cells, and (2) a more intriguing complex assembled over the telomerase-repeat binding protein (TRF) and then, presumably located at telomers.

In the present report, we demonstrate that *TcBDF2* is essential for the development of both epimastigotes and intracellular amastigotes and validate it as a target for the search of new trypanocidal drugs using commercial bromodomain inhibitors.

Results and discussion

TcBDF2 gene (*TcBDF2*) is essential in epimastigotes

In order to investigate how *TcBDF2* is involved in different aspects of *T. cruzi* physiology, we tried to generate a *TcBDF2* knockout mutant line and evaluate the resulting phenotypes. We followed the CRISPR/Cas9 genome editing strategy reported by Lander *et al* 2015³⁷, which is outlined in Figure 1A³⁷. Briefly, the sgRNA targeting *TcBDF2* sequence was cloned into the pTREXCas9 vector and co-transfected into the parasite with the donor DNA. The sgRNA guides the Cas9 complex to the specific site in the DNA and produces a double-strand break in the DNA of the selected gene. Then, this rupture induces the DNA to be repaired by double homologous recombination in the presence of a donor DNA that carries a selectable marker (blasticidin in this case). Once the resistant parasites were selected we isolated the genomic DNA and corroborated donor DNA insertion by PCR (Figure 1B, inset). Despite three attempts to knockout *TcBDF2*, we were only able to obtain parasites with only one mutated copy of the gene, suggesting that *TcBDF2* is an essential gene for epimastigotes. As it is shown in Figure 1B we evaluated the proliferation of epimastigotes of the heterozygous line and determined that there were no significant differences regarding the growth rate when compared to the control line, indicating that one copy of the gene is enough for epimastigote normal growth.

Figure 1. (A) Schematic representation of *TcBDF2* mutation by CRISPR/Cas9 genome editing. The whole strategy was designed to replace the *TcBDF2* coding sequence with a blasticidin resistance gene (BST^R). Taking the adenine of the initial codon as zero, numbers indicate the start and end of each homology region. The protospacer sequence and cutting site position are also indicated. The arrows represent the oligonucleotides employed to determine the presence of the mutation. (B) Growth curve of epimastigotes transfected with scramble sgRNA (black squares, Scr) or BDF2^{-/-} (blue circles) cells, counted daily for 10 days. The KO allele generates an 1166 pb PCR product while the WT PCR product size is 866 pb with the oligonucleotides indicated in A (inset (B)).

TcBDF2 bears a functional canonical NLS within its C-terminal domain.

As mentioned before, several attempts to establish a stable KO line by CRISPR/Cas9 were carried out and despite our effort, we were not able to knockout *TcBDF2* completely. Therefore, we decided to pursue a different methodological approach to deepen the knowledge of *TcBDF2* in the parasite life cycle. We made use of the vector p*TcINDEX*GW, a GATEWAY® Cloning Technology-adapted version of p*TcINDEX*³⁸ built in our laboratory. This plasmid allowed us to

overexpress our protein of interest under the control of a tetracycline-regulated promoter in all the stages of the *T. cruzi* life cycle^{38,39}.

First, we constructed different truncated versions of *TcBDF2* to determine the localization of its predicted nuclear localization signal (NLS). *In silico* study of *TcBDF2* amino acid sequence by NLstradamus⁴⁰ predicted a complete nuclear localization site (NLS) between the amino acids R162 and N177, which is present in BDF2 from all *T. cruzi* strains, but absent in *Leishmania* spp and *T. brucei*. To test their functionality, we cloned the full coding sequence of *TcBDF2* (*TcBDF2HA*) as well as truncated mutants with (*TcBDF2Δ177*) or without (*TcBDF2Δ162*) the largest predicted NLS region, into the plasmid p*TcINDEX*-GW. These constructs were tagged with an epitope of hemagglutinin (HA) at the N-terminus and used to transfect Dm28c epimastigotes (Fig. 2A).

Figure 2. A Schematic representation of the truncated versions of *TcBDF2* B. Localization of *TcBDF2HA* (wild type) and C-terminal truncated proteins (HA-tagged) analyzed by immunofluorescence with anti HA antibodies (α-HA). Images were obtained using monoclonal rat anti-HA antibodies developed by anti-rat IgG antibody conjugated to Alexa 488 (green). The nucleus (N) and kinetoplast (K) were labeled with DAPI. The scheme on the left shows the different mutated versions of *TcBDF2* which expression pattern in epimastigotes is shown on the right. The bromodomain portion of the protein is indicated as BRD and the predicted Nuclear Localization Signal is indicated as NLS. Scale bar = 5 μm.

As expected, *TcBDF2HA* was directed to the nucleus (Fig. 2B), giving a strong nuclear signal in the epimastigote stage when immunolocalized with anti-HA antibodies. We have previously reported that *TcBDF2* is localized in the nucleus under physiological conditions³⁴. On the contrary, when we overexpressed the mutated version *TcBDF2Δ162*, a clear change in the localization of the signal from the nucleus to the cytosol was observed. But when we overexpressed *TcBDF2Δ177HA*, the nuclear localization was detected again (Fig. 2B). These results clearly show that the NLS predicted is responsible for targeting and retaining *TcBDF2* in the nucleus.

It has been proposed that the functional monopartite NLS in *T. brucei* KRxR, a sub-motif of a classical eukaryotic NLS, is the characteristic NLS for trypanosomatids⁴¹. When we inspected the NLS predicted region in detail we observed that *TcBDF2* shows also a monopartite NLS at the N terminus between the amino acids R3 and K6. This putative signal (KRGR) is well conserved in

all *T. cruzi* strains and *Leishmania* spp (KRPR) but absent in the *T. brucei* homolog. However, it is clearly not able to target *TcBDF2*Δ162 to the nucleus, suggesting that is not functional in *T. cruzi*, as has been proposed by Goos *et al* for trypanosomatids based in the *T. brucei* nuclear proteome ⁴¹. Even though further studies will be necessary to determine which specific amino acid/s is/are responsible within the NLS for the localization of *TcBDF2* to the nucleus, it is clear that the canonical NLS, present in *T. cruzi* but absent in other trypanosomatids, is one of the many differences that the bromodomain-containing protein family show among trypanosomatids.

Overexpression of both wild type and mutant *TcBDF2* produces a detrimental effect on epimastigote growth.

Next, we generated *TcBDF2* constructs with two single point mutations that change essential amino acids located at the hydrophobic pocket of the BD. Previously, we demonstrated that the change of two conserved hydrophobic amino acids of *TcBDF3* to alanines abolished the capability of the protein to recognize its ligand, but at the same time, the overall protein-folding remains unaltered. Following the same strategy, we identified and selected Y85 and W92 to be substituted by alanine residues (hereinafter *TcBDF2HAdm*).

TcBDF2dm and *TcBDF2* wild type constructs were cloned in the p*TcINDEX*-GW plasmid with HA tags and were transfected to epimastigotes. This overexpression approach of a mutant BD has been successfully used by our group to generate a dominant-negative phenotype that was unable to bind to its acetylated target ^{24,32}.

We corroborated the correct expression of the inducible system by western blot analyses of both *TcBDF2HAWt* and *TcBDF2HAdm*. As can be seen in Figures 3 A and B (right panel), we detected only one band of the expected molecular weight when probed with an α-HA antibody. Even though correct folding of *TcBDF2HAdm* was not verified when expressed in *T. cruzi*, both the wild type and mutant bromodomain were demonstrated to be folded after expression and purification from *E. coli* (see below). *TcBDF2HAdm*, as well as *TcBDF2HA*, were also detected in the nucleus when IFA was performed using an α-HA antibody (Supplementary Figure 1).

To evaluate the effect of overexpression of *TcBDF2HA* and *TcBDF2HAdm* on epimastigote replication we performed growth curves in the presence (tet+) and absence (tet-) of tetracycline for 8 days. As seen in Figures 3A and B (left panel), the expression of wild type and mutant *TcBDF2* affects epimastigote growth, when compared with the uninduced parasites. In fact, the effect is higher when the wild type version is overexpressed. These results did not change when a 10-times less amount of tetracycline was used (not shown). These data suggest that the correct endogenous level of a functional *TcBDF2* is essential for the normal progression of the epimastigote cell cycle since overexpression of *TcBDF2HA* or of a protein unable to recognize the acetylated lysine (*TcBDF2HAdm*), even in low amounts produces a halt in epimastigote normal proliferation. When the distribution of parasites along the cell cycle was tested by flow cytometry in non-synchronized cultures, no evident differences were observed between non-induced and *TcBDF2*-induced cultures until 72 hs. However, in *TcBDF2dm*-induced cultures a population of parasites with DNA content lower than 2n appears, which was increased from approximately 5%

at 24 hs to 8.2 % at 72 hs (Supplementary Figure 2). The appearances of this population could indicate that these parasites may be entering either an apoptotic or necrotic process. This phenomenon strongly suggests that the mechanisms by which overexpression of wild type or mutant *TcBDF2* affect the parasites are not the same.

Figure 3: *TcBDF2HA* and *TcBDF2HAdm* overexpression decreases cell proliferation. Growth curve of epimastigotes transfected with p*TcINDEX*-GW-*TcBDF2HA* (A) or p*TcINDEX*-GW-*TcBDF2HAdm* (B) in the absence (blue circles, Tet-) or presence (black squares, Tet+) of 0.5 μ g/ml tetracycline, counted daily for 8 days. Tetracycline-induced protein overexpression was tested by western blot analysis using monoclonal rat anti-HA antibodies. Values represent means $\pm$ SD of 3 independent replicates.

***TcBDF2* affects *T. cruzi* performance on mammalian host Infection.**

To better evaluate the potential of *TcBDF2* as a druggable target for Chagas disease treatment, we examined the involvement of this bromodomain factor on *T. cruzi* infective stages in the mammalian host. We evaluated if *TcBDF2* was able to modulate the infectivity of the parasite by allowing the parasites to invade Vero cells with *T. cruzi* transgenic lines overexpressing *TcBDF2HA* or *TcBDF2HAdm*. Given the advantage of the overexpression system which allows us to induce the production of the proteins at different time points, we were able to analyze how the overexpression of *TcBDF2HA* or *TcBDF2HAdm* affects *T. cruzi* performance throughout the entire infection process. The experimental details are described under the Methods section but briefly, trypomastigotes were pre-incubated with tetracycline (Figure 4, +/- and +/+ condition) or not (-/+ and -/- condition) and then allowed to infect a monolayer of Vero cells. After 6 hs free trypomastigotes were washed out and fresh medium with (+/+ and -/+ condition) or without tetracycline (+/- and -/- condition) was added to the cells and incubated for 3 days. The -/- condition represents the non-induced control where tetracycline was never added to the medium and the +/+ condition shows the effect of protein overexpression during the whole infection assay. First, we measured the ability of the overexpressing trypomastigotes to invade Vero cells. As can be seen in Figure 4A, the percentage of cells infected under the conditions (+/-) and (-/-) showed no statistical differences for both *TcBDF2HA* and *TcBDF2HAdm*. Trypomastigotes are considered the form with the lowest levels of active transcription in the life cycle of *T. cruzi*. Considering that *TcBDF2* is a protein that participates in complexes related to the transcriptional capacity of chromatin, it is not surprising that an imbalance of this protein, whether in its wild type or mutated form, does not have a marked effect on the physiology of this stage of the parasite.

Figure 4: Overexpression of *TcBDF2HAdm* alters intracellular replication and trypomastigote release. The infection performance of *T. cruzi* Dm28c transfected with pTcINDEX-GW-*TcBDF2HA* or pTcINDEX-GW-BDF2HAdm were analyzed in the absence (Tet-) or presence (Tet+) of 0.5 µg/ml tetracycline. To test the effect over the different phases of infection, we designed different induction protocols as follows: (-/-), Tet was never added to the medium, non-induced control; (+/-), trypomastigotes were pre-treated with Tet for 2 hours before infection, and during the invasion incubation period but not after; (-/+), trypomastigotes were not induced, Tet was only added after infection to see the effect on the amastigote stage; (+/+), trypomastigotes were pre-treated and Tet was present during the whole infection assay, to see the overexpression effect on both trypomastigotes and amastigotes. The percentage of infected cells (A), the number of amastigotes per cell (B), and the number of trypomastigotes released 6 days post-infection (C) were determined by counting Giemsa-stained slides using a light microscope. Results are expressed as means ± SD of triplicates. Statistical analysis of the data was carried out using one-way ANOVA, * $p < 0.05$, ** $p < 0.001$ and *** $p < 0.005$.

Moving forward in the infection process we also evaluated how *TcBDF2* affects amastigote proliferation. Intracellular amastigote replication was measured as the average number of intracellular amastigotes per infected cell at 72 hs post-infection. Figure 4B represents the average numbers of amastigotes per cell for all the induction conditions when both *TcBDF2HA* and *TcBDF2HAdm* were overexpressed. As it can be observed, when *TcBDF2HA* was overexpressed we did not detect any significant difference in the number of amastigotes among all the conditions assayed but strikingly we observed a significant decrease of about 50% in the amastigote proliferation when *TcBDF2HAdm* was overexpressed. It is worth to highlight that this behavior was opposite to that observed in epimastigotes, where the overexpression of the wild type protein triggers the higher detrimental effect as shown in Figure 1.

Finally, we focused on the amastigote/trypomastigote differentiation and trypomastigote release from the infected cells. After 4 days post-invasion, trypomastigotes started to be released to the medium from the infected Vero cells. To analyze how *TcBDF2* impacts these final steps it is important to compare the (-/+) vs (-/-) conditions taking into account that the final result is a sum of all the processes happening once the initial trypomastigote invades the cell until the new trypomastigotes are released for further infections. As it can be seen in Figure 4C, the overexpression of *TcBDF2HA* affects negatively the final steps reducing approximately by 50% the number of released parasites. However, when *TcBDF2HAdm* was overexpressed we noticed a sharp decrease in trypomastigote released since parasites were practically undetectable in the culture medium.

Taken together, all these results indicate that *TcBDF2*, or better the complexes that include it, are essential for epimastigote and amastigote replication and for amastigote differentiation to trypomastigotes. However, the dissimilar response of the different life cycle stages to the increased levels of *TcBDF2* and *TcBDF2dm* suggests a complex landscape, where more than one protein complex could be playing a variety of roles. Even though the elucidation of the composition of these complexes and their function is beyond the objectives of this work, our results validate *TcBDF2* as a target for the development of new drugs against Chagas disease.

Recombinant *TcBDF2HA* interacts with bromodomain inhibitors.

Once demonstrated that *TcBDF2* is essential for almost all life cycle stages of *T. cruzi*, we tested the ability of small molecules that can act as bromodomain inhibitors to bind *TcBD2*. In this case, we made use of an autofluorescence quenching assay, due to the presence of a tryptophan in the hydrophobic pocket, previously validated with *TcBDF3*³³. Briefly, we obtained the intrinsic fluorescence spectrum of each protein and evaluated the changes they underwent upon adding increasing amounts of each inhibitor (Figure 5). In this case, we assayed the recombinant bromodomain portion of *TcBDF2* (*TcBD2*) and *TcBDF2HAdm* (*TcBD2dm*). Both fragments were obtained by cloning and overexpressing them in a soluble manner in *E.coli*-BL21 using the commercial plasmid pDEST17. The folding of the purified bromodomains was compared by circular dichroism, corroborating that the spectra, corresponding to the presence of alpha helices, was identical for both the wild type and the mutated domain (Supplementary Figure 3).

As can be observed in Figure 5A, *TcBD2* intrinsic fluorescence decreased in the presence of the human/commercial bromodomain inhibitors iBET151, RVX-208, and Bromosporin (BSP) but remained unaltered with the other inhibitors assayed. However, no variation in the intrinsic fluorescence of the mutated version (Figure 5B) was observed when incubated with these compounds, indicating that the interaction depends on the integrity of the *TcBDF2* hydrophobic pocket. The data was further examined using the modified Stern-Volmer equation to calculate the dissociation constants (*K_d*), which was around 14 μ M for iBET-151 and BSP but significantly higher for Rvx-208 (Figure 4C). *K_d* values we also calculated by thermal shift obtaining similar results. The complete fluorescence spectra of the wild type and mutant *TcBDF2* in the presence of increasing concentrations of BSP are shown in Figure 5E. Bromosporin also blocked the

interaction of recombinant *TcBDF2* with a peptide derived from histone H4 acetylated on lysines 4, 10, and 14, as seen by far-western blot (Figure 5D). This supports the idea that the inhibitors are recognized by the hydrophobic pocket of the bromodomain and compete with its ligand.

Figure 5: *TcBDF2HA* interacts with acetylated histone H4 and three human bromodomain inhibitors. Normalized intrinsic fluorescence of recombinant *TcBDF2HA* (A) and *TcBDF2dmHA* (5 μ M) (B) with an increasing amount of the indicated bromodomain inhibitor (10, 20, 40 μ M). (C) Dissociation constants (K_d) of iBET-151, Rvx-208, and Bromosporine (BSP) were calculated from double logarithmic plots of the intrinsic fluorescence spectra of BDF2HA with the compounds. (D) Slot far-western blot assay. Tri-acetylated and non-acetylated (H4Ac) histone H4 (H4) peptides were blotted onto a nitrocellulose membrane and incubated with HA-tagged recombinant *TcBDF2* in the absence and presence of Bromosporine. The bound recombinant protein was detected with anti HA antibodies (α -HA). (E) Fluorescent spectra of BDF2wt (left) and BDF2m (right) with increasing concentrations of BSP (0 to 200 μ M) and fixed concentration of protein 30 μ M.

TcBDF2 was co-crystallized previously with BSP at its hydrophobic pocket. When we modeled by local docking this interaction using RosettaLigand⁴², BSP was found at the same position than in the crystal structure indicating that our settings were correct (Supplementary Figure 4A-B). Using the same approach we modeled the interaction of *TcBDF2* with the inhibitors we tested *in vitro* and calculated the interphase energy and the root mean square deviation (RMSD) (Supplementary Figure 4C). The results of this *in silico* evaluation of the interactions between *TcBDF2* and the compounds mentioned in Figure 5 correlates with the dissociation constants obtained by quenching of the intrinsic tryptophan fluorescence, further validating this assay (Supplementary Figure 4D).

When our results are compared with those obtained previously by analyzing the same panel of bromodomain inhibitors against recombinant *TcBDF3*⁴³, it can be clearly seen that *TcBDF2* and *TcBDF3* have different binding specificities. iBET-151 binds to both bromodomains with similar affinity, but JQ1(+), which binds *TcBDF3* with an affinity similar to iBET-151, does not interact with *TcBDF2*. In contrast, BSP shows a higher affinity for *TcBDF2* than for *TcBDF3*.

As it was already mentioned, some bromodomains inhibitors were also already tested against *T. brucei*, but results are significantly different when the orthologs are compared. Shultz and coworkers³⁶ showed that iBET-151 binds to *TbBDF2* and *TbBDF3* with a low affinity ($K_d = 225 \mu\text{M}$ and $175 \mu\text{M}$, respectively). Surprisingly, when iBET-151 was co-crystallized with *TbBDF2* it was found in a completely atypical position, flipped by roughly 180° to the position it binds to human BDs, something that could explain the low affinity of the interaction. Later, Yang *et al.* described a compound, GSK2801, that binds with high affinity ($K_d = 15 \mu\text{M}$) to the BD from *TbBDF2* and with low affinity ($K_d = 83 \mu\text{M}$) to the second BD from *TbBDF5*. In contrast, GSK2801 did not bind to *TbBDF3* and neither to the first BD from *TbBDF5*¹⁵.

Conclusions

We have previously demonstrated that *TcBDF1* and *TcBDF3* are two essential bromodomain-containing proteins for the parasite to accomplish their life cycle by using a dominant-negative approach (ref). More recently, it was not possible to generate full knockouts for these genes by CRISPR/Cas9. Herein, using similar tools, we showed that *TcBDF2* is also essential for both epimastigote and amastigote growth. We also showed that bromodomain inhibitors can bind to *TcBDF2* through its hydrophobic pocket. However, the specific binding profile is different for *TcBDF2* than for *TcBDF3*. Our results, together with those obtained for other parasites, show that parasite bromodomains, despite their structural preservation, are a family with a great diversity at the level of substrate specificity. This is observed both between proteins from different species (like *T. brucei* and *T. cruzi*) and between proteins from the same species, as we observed for *TcBDF2* and *TcBDF3*. These observations establish that it is possible to find molecules with high binding specificity that can discriminate between parasite bromodomains and human bromodomains, reinforcing the idea that they can be tested as antiparasitic compounds.

Methods.

Parasite cultures.

T. cruzi Dm28c epimastigotes were cultured at 28°C in LIT medium (5 g/L liver infusion, 5 g/L bacto-tryptose, 68 mM NaCl, 5.3 mM KCl, 22 mM Na_2HPO_4 , 0.2% (w/v) glucose and 0.002% (w/v) hemin) supplemented with 10% (v/v) heat-inactivated, UV-irradiated Fetal Calf Serum (FCS) (Internegocios S.A, Argentina).

Molecular cloning of *TcBDF2HA*.

TcBDF2 gene (*TCDM_14496*) was amplified by PCR from *T. cruzi* Dm28c genomic DNA using the following oligonucleotides: *TcBDF2HA*w, designed to add a hemagglutinin (HA) tag at the N-terminus of the protein (5'-AAAGGATCCATGTATCCGTATGATGTGCCGATTATGCTGGGAAGCGTGGGCGT-3'), and *TcBDF2R*v (5'-AAAGATATCTTATTCATCATCACTCTCATCATCATAATAAACTCTTC-3'). Truncated

protein was constructed using the following reverse oligonucleotides: Δ C177-*TcBDF2*Rv (5'-AAAGATATCTTAATTCTTGCTCCTTTCTTCTTTTCCACAC-3'), Δ C162-*TcBDF2*Rv (5'-AAAGATATCTTAAGCTCCTCCAG-3') Δ C117-*TcBDF2*Rv (5'-AAAGATATCTTACGCGTCGTCGTCACACTCAG-3'). The last construction corresponds to the bromodomain portion of *TcBDF2* and was employed to purify it as a recombinant protein for *in vitro* assays. The double mutant *TcBDF2*HAdm (*TcBDF2*Y85A/W92A) was constructed using a PCR-based site-directed mutagenesis strategy with the following oligonucleotides: *TcBDF2*Y85AFw (5'-CTGCGAGAAGGCTAACGGCG-3'), *TcBDF2*Y85ARv (5'-CGCCGTTAGCCTTCTCGCAG-3'), *TcBDF2*W92AFw (5'-CGACTCCGCTGCGGTTAAAG-3') and *TcBDF2*W92ARv (5'-CTTTAACCGCAGCGGAGTCG-3'). The PCR products were first cloned into the pCR2.1-TOPO vector (Invitrogen) and sequenced. The coding sequences were sub-cloned into a pENTR-3C vector (Invitrogen) using BamHI/EcoRV restriction sites included in the oligonucleotides (underlined) and then transferred to the p*Tc*INDEX-GW and to pDESTTM17 (Gateway System, Invitrogen) vector by recombination using LR clonase II enzyme mix (Invitrogen).

***TcBDF2* KO line generation.**

The general strategy was carried out as is indicated by Lander *et. al* 2016. Briefly, the sgRNA carrying the specific protospacer sequence was amplified from pUC_sgRNA plasmid using the oligonucleotides SgRNAFw (5'-GATCGGATCCGCGTGAGGGGACTTTGGACAGTTTTAGAGCTAGAAATAGC-3') and SgRNARv (5'-CAGTGGATCCAAAAAAGCACCGACTCGGTG-3') and cloned into Cas9/pTREX-n plasmid by using BamHI site (underlined in the primers). Donor DNA was generated by PCR using as a template the blasticidin-S deaminase gene (*Bsd*). Ultramers utilized were *TcBdf2*KOFw (5'-ATAAAAGAAGAGGCACACAGAAAACAAAGAAAGCCGTCGAAATAATAAAGAAACAACAACAACAAGAGAGGCCTGGAGGTAACAGTATCGGGGGGTGATGGCCAAGCCTTTGTCTCA-3') and *TcBdf2*KORv (5'-GCTGTCGTACTTTCCGGACTCAATGCCCTGACGAATTGTCGACAGGTCAACAGGATAATTTATGACCTTGTGGTAGTCCGGCAGCTCCGCAGCGCTGATTTTACCCCTCCCACACATAAC-3'). The sequences of the 120 pb ultramers included the homology region for DNA recombination. *T. cruzi* DM28c epimastigotes were co-transfected with the donor DNA and Cas9/pTREX-n plasmid and the parasites were selected by adding G418 and blasticidin in the medium as indicated in ⁴⁴. A scrambled sgRNA (Scr-sgRNA/Cas9/pTREX-n) was used as control as described by Lander *et al* (2016).

Protein purification.

Protein purification pDEST17-*TcBDF2* and pDEST17-*TcBDF2*m were transformed into *Escherichia coli* BL21, and the recombinant proteins (fused to a His-tag) were obtained by induction with 0.1 mM isopropyl-b-D-thiogalactopyranoside overnight at 22 °C. The protein was purified using Ni-NTA (Thermo FisherTM) following the manufacturer's instructions. Purified proteins were dialyzed against 0.1 M phosphate buffer pH 8. The secondary structure of soluble

proteins was measured by circular dichroism spectroscopy using a spectropolarimeter (Jasco J-810, Easton, MD, USA).

Transgenic parasite generation.

Epimastigotes from *T. cruzi* Dm28c were transfected with the pLEW13 plasmid to generate parasites expressing T7 RNA polymerase and the Tet repressor using a standard electroporation method. Briefly, epimastigotes were cultured in LIT medium at 28 °C to a final concentration of $3\text{--}5 \times 10^7$ parasites/ml. Then, parasites were harvested by centrifugation at 1500 g for 5 min at room temperature, washed twice with phosphate-buffered saline (PBS), and resuspended in 0.35 ml transfection buffer (0.5 mM MgCl₂, 0.1 mM CaCl₂ in PBS, pH 7.5) to a density of 1×10^8 cells/ml for each transfection. Electroporation was performed in a 0.2 cm gap cuvette (Bio-Rad) with ~40 µg of plasmid DNA added to a final volume of 400 µl. The parasite-DNA mixture was kept on ice for 25 min and subjected to a 450 V, 500 µF pulse using GenePulser II (Bio-Rad, Hercules, USA). After electroporation, cells were transferred into 3 ml of LIT medium containing 10% FCS, maintained at room temperature for 15 minutes, and then incubated at 28 °C. Geneticin (G418; Life Technologies) was added at a concentration of 200 µg/ml, and parasites were incubated at 28 °C. After selection, pLEW13 transfected epimastigotes were maintained in the presence of 200 µg/ml of G418. This parental cell line was then transfected with p*Tc*INDEX-GW-*TcBDF2HA* (WT and mutant versions) plasmids following a similar protocol and transgenic parasites were obtained after 3 weeks of selection with 100 µg/ml G418 and 200 µg/ml Hygromycin B (Sigma).

***T. cruzi* infection of Vero cells.**

Vero cells (ATCC CCL-81) were cultured in Dulbecco's Modified Eagle Medium (DMEM) (ThermoFisher), supplemented with 2 mM L-glutamine, 10% FCS. For the first round of infection, metacyclic trypomastigotes were obtained by spontaneous differentiation from late-stationary phase cultured epimastigotes at 28 °C. Cell-derived trypomastigotes were obtained by infection with metacyclic trypomastigotes in Vero cell monolayers. For the infection and amastigote proliferation experiments, we used cell-derived trypomastigotes released from the second round of infection. Trypomastigotes were collected from the supernatant of the infected cells culture, harvested by centrifugation at 5000 g for 10 min at room temperature, resuspended in DMEM, and counted in a Neubauer chamber. When indicated, the parasites were pre-incubated with Tet (0.5 µg/ml) for 2 hs to allow protein induction, and a new monolayer of cultured Vero cells was infected with a MOI of 10:1. After a 6 hs-incubation at 37 °C, the free trypomastigotes were removed by washes with PBS. This pre-treatment of trypomastigotes with tetracycline before infection and during the 6 hs-incubation to allow invasion is indicated with a "+" before the bar "(+)". Then, infected Vero cell cultures were incubated in DMEM supplemented with 2% FCS with or without Tet (0.5 µg/ml) for three days. The presence of Tet during this incubation period when amastigotes replicate inside the infected cell is indicated by the "+" after the bar "(+)". The experiments were stopped by cell fixation with methanol and the percentage of infected cells and the mean number of amastigotes per infected cell were determined by direct slide counting (Nikon Eclipse Ni-U

microscope). Giemsa staining was used for amastigotes visualization and approximately 800 cells were counted per slide. Alternatively, after 4 days post-infection, the supernatant from monolayer infection was taken to determine the number of trypomastigotes released from cells. The significance of the results was analyzed with two-way ANOVA using GraphPad PRISM version 6.0 for Mac (GraphPad Software, La Jolla, CA, USA). Results are expressed as means $\pm$ SEM of triplicates, and represent one of three independent experiments performed.

Western blot analysis.

Protein extracts were fractioned in SDS-PAGE and transferred to a nitrocellulose membrane. Transferred proteins were visualized with Ponceau S staining. Membranes were treated with 10% non-fat milk in PBS for 2 hs and then incubated with specific antibodies diluted in 0.5% Tween20 in PBS (PBS-T) for 3 hs. Antibodies used were: rat monoclonal anti-HA (ROCHE), affinity-purified rabbit polyclonal anti-BDF2, mouse monoclonal anti-trypanosome α -tubulin clone TAT-1 (a gift from K. Gull, University of Oxford, UK). Bound antibodies were detected using peroxidase-labeled anti-rabbit IgG (GE Healthcare), or anti-rat IgG (Thermo Scientific) and developed using ECL Prime kit (GE Healthcare) according to manufacturer's protocols. Immunoreactive bands were visualized using an AmershamTM Imager 600 digital imager.

Immunofluorescence.

Mid-log epimastigotes were harvested by centrifugation at 1500 g for 5 min at room temperature and washed twice before fixation in 4% paraformaldehyde solution. Fixed parasites were placed on a coverslip pre-coated with poly L-lysine for 20 min and then washed with PBS. Permeabilization was done with 0.2% Triton X-100 solution for 10 min. After washing with PBS, parasites were incubated with the appropriate primary antibody diluted in 1% BSA in PBS for 2 hs at room temperature. Non-bound antibodies were washed with PBS-T and then the slides were incubated with anti-HA (Roche) and anti-rat IgG::FITC (Life Technologies) and 2 μ g/ml 4',6-diamidino-2-phenylindol (DAPI) for 1 h. The slides were washed again with PBS-T and mounted with VectaShield (Vector Laboratories). Images were acquired with a confocal microscope ZEISS LSM 880. Adobe Photoshop CS and ImageJ software were used to process all images.

Flow cytometry.

One million cells were fixed with cold 70% ethanol and then washed with PBS and stained with 20 μ g/ml Propidium Iodide (PI) in buffer K (0.1% sodium citrate, 0.02 mg/ml RNase A (Sigma), and 0.3% NP-40. Ten thousand events per sample were acquired using BD Cell Sorter BD FACSARIA II. Results were analyzed using FlowJo software.

Far Western blot and slot blot.

Far Western blots were performed using 10 μ g of each 16 amino acid-long peptides derived from the histone H4 sequence, or the same sequence with acetylated lysines 4, 10, and 14 (CAKGGKacKSGEAKaGTQKaRQ, immobilized onto a nitrocellulose membrane. Peptides were visualized by Ponceau S staining. The membranes were treated with 5% non-fat milk in PBS

(blocking buffer) for 2 hs, and then with recombinant *TcBDF2HA* diluted in blocking buffer (0.1 and 0.5 µg/ml) for 1 h. After this incubation, membranes were washed with PBS Tween 0.1%. Bound proteins were visualized using rat anti-HA antibody and detected using peroxidase-labeled anti-rat IgG antibody and ECL Plus (GE Healthcare).

Protein purification.

pDEST17-*TcBDF2HA* and pDEST17-*TcBDF2HAdm* were transformed into *Escherichia coli* BL21, and the expression of recombinant proteins (fused to a His-tag and haemagglutinin tag) were induced with 0.1 mM isopropyl-β-D-thiogalactopyranoside during 5 hs at 37 °C. The proteins were purified under native conditions by affinity chromatography using Ni-NTA agarose (Qiagen) following the manufacturer's instructions.

Fluorescence spectroscopy.

A 2 mL solution containing 5 µM recombinant *TcBDF2HA* or *TcBDF2HAdm* was titrated by successive addition of the bromodomain inhibitors using concentrations ranging from 0 to 50 µM. Fluorescence spectra were acquired with an excitation wavelength of 295 nm and emission was recorded in the range of 300–450 nm. All fluorescence measurements were corrected with a blank solution and with the emission spectra of each concentration of inhibitor. Taking into account the inner filter effect in the quenching process, we corrected the fluorescence intensity of *TcBDF2* using the following equation⁴⁵ (Samworth et al., 1988): $F_{\text{corr}} = F_{\text{obs}} \times 10^{(A_{\text{exc}} + A_{\text{em}})/2}$, where F_{corr} and F_{obs} are the corrected and observed fluorescence intensity of *TcBDF2HA*, and A_{exc} and A_{em} are the absorption values of the system at the excitation and emission wavelength, respectively.

Statistical analysis.

Experiments were performed in triplicate, and at least three independent experiments were performed. Data are presented as the mean ± SEM. Statistical analysis of the data was carried out using two-way ANOVA and unpaired two-tailed Student's t-test. Differences between the experimental groups were considered significant as follows: * $P < 0.05$, ** $P < 0.001$ and *** $P < 0.005$.

Acknowledgments

This work was supported by Agencia Nacional de Ciencia y Tecnologia from Argentina (PICT-2014-2593, PICT-2017-1978), Universidad Nacional de Rosario (1BIO490), Research Council United Kingdom (MR/P027989/1) and GlaxoSmithKline. We would like to thank Dolores Campos and Dr. Romina Manarin for their technical assistance with Vero cell and parasites culture, to Mara Ojeda for technical assistance with flow cytometry and to Dr. Teresa Cruz-Bustos for discussions on the use of CRISPR/Cas9. Part of the results presented in this work have been obtained by using the facilities of the CCT-Rosario Computational Center, member of the High Performance Computing National System (SNCAD, MincyT-Argentina).

Bibliography

1. Requena-Méndez A, Aldasoro E, de Lazzari E, et al. Prevalence of Chagas Disease in Latin-American Migrants Living in Europe: A Systematic Review and Meta-analysis. *PLoS Negl Trop Dis*. Published online 2015. doi:10.1371/journal.pntd.0003540
2. WHO. WHO | Chagas disease (American trypanosomiasis) Factsheet. WHO.
3. Sales PA, Molina I, Murta SMF, et al. Experimental and clinical treatment of Chagas disease: A review. *Am J Trop Med Hyg*. Published online 2017. doi:10.4269/ajtmh.16-0761
4. Martínez-Calvillo S, Vizuet-De-Rueda JC, Florencio-Martínez LE, Manning-Cela RG, Figueroa-Angulo EE. Gene expression in trypanosomatid parasites. *J Biomed Biotechnol*. Published online 2010. doi:10.1155/2010/525241
5. De Gaudenzi JG, Carmona SJ, Añuero F, Frasch AC. Genome-wide analysis of 3'-untranslated regions supports the existence of post-transcriptional regulons controlling gene expression in trypanosomes. *PeerJ*. Published online 2013. doi:10.7717/peerj.118
6. Rudenko G. Epigenetics and transcriptional control in African trypanosomes. *Essays Biochem*. Published online 2010. doi:10.1042/BSE0480201
7. Staneva DP, Carloni R, Auchynnikava T, et al. A systematic analysis of Trypanosoma brucei chromatin factors identifies novel protein interaction networks associated with sites of transcription initiation and termination. *Genome Res*. Published online 2021. doi:10.1101/gr.275368.121
8. Jones NG, Geoghegan V, Moore G, et al. Bromodomain factor 5 is an essential transcriptional regulator of the Leishmania genome. *bioRxiv*. Published online January 1, 2021:2021.09.29.462384. doi:10.1101/2021.09.29.462384
9. Felsenfeld G, Groudine M. Controlling the double helix. *Nature*. Published online 2003. doi:10.1038/nature01411
10. Kouzarides T. Chromatin Modifications and Their Function. *Cell*. Published online 2007. doi:10.1016/j.cell.2007.02.005
11. Respuela P, Ferella M, Rada-Iglesias A, Åslund L. Histone acetylation and methylation at sites initiating divergent polycistronic transcription in Trypanosoma cruzi. *J Biol Chem*. Published online 2008. doi:10.1074/jbc.M802081200
12. Siegel TN, Hekstra DR, Kemp LE, et al. Four histone variants mark the boundaries of polycistronic transcription units in Trypanosoma brucei. *Genes Dev*. Published online 2009. doi:10.1101/gad.1790409
13. Thomas S, Green A, Sturm NR, Campbell DA, Myler PJ. Histone acetylations mark origins of polycistronic transcription in Leishmania major. *BMC Genomics*. Published online 2009. doi:10.1186/1471-2164-10-152
14. Reynolds D, Hofmeister BT, Cliffe L, et al. Histone H3 Variant Regulates RNA Polymerase II Transcription Termination and Dual Strand Transcription of siRNA Loci in Trypanosoma brucei. *PLoS Genet*. Published online 2016. doi:10.1371/journal.pgen.1005758
15. Yang X, Wu X, Zhang J, et al. Recognition of hyperacetylated N-terminus of H2AZ by TbBDF2 from Trypanosoma brucei. *Biochem J*. Published online 2017. doi:10.1042/BCJ20170619
16. Wedel C, Förstner KU, Derr R, Siegel TN. GT-rich promoters can drive RNA pol II

- transcription and deposition of H2A.Z in African trypanosomes . *EMBO J*. Published online 2017. doi:10.15252/embj.201695323
17. Anderson BA, Wong ILK, Baugh L, Ramasamy G, Myler PJ, Beverley SM. Kinetoplastid-specific histone variant functions are conserved in *Leishmania major*. *Mol Biochem Parasitol*. Published online 2013. doi:10.1016/j.molbiopara.2013.09.005
18. Rosón JN, de Oliveira Vitarelli M, Costa-Silva HM, et al. Histone H2B.V demarcates strategic regions in the Trypanosoma cruzi genome, associates with a bromodomain factor and affects parasite differentiation and host cell invasion. *bioRxiv*. Published online 2021.
19. Berná L, Rodríguez M, Chiribao ML, et al. Expanding an expanded genome: long-read sequencing of *Trypanosoma cruzi*. *Microb genomics*. Published online 2018. doi:10.1099/mgen.0.000177
20. Zaware N, Zhou MM. Bromodomain biology and drug discovery. *Nat Struct Mol Biol*. Published online 2019. doi:10.1038/s41594-019-0309-8
21. Vidler LR, Brown N, Knapp S, Hoelder S. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. *J Med Chem*. Published online 2012. doi:10.1021/jm300346w
22. Sanchez R, Meslamani J, Zhou MM. The bromodomain: From epigenome reader to druggable target. *Biochim Biophys Acta - Gene Regul Mech*. Published online 2014. doi:10.1016/j.bbagr.2014.03.011
23. Kulikowski E, Rakai BD, Wong NCW. Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases. *Med Res Rev*. Published online 2021. doi:10.1002/med.21730
24. Alonso VL, Ritagliati C, Cribb P, Cricco JA, Serra EC. Overexpression of bromodomain factor 3 in *Trypanosoma cruzi* (TcBDF3) affects differentiation of the parasite and protects it against bromodomain inhibitors. *FEBS J*. Published online 2016. doi:10.1111/febs.13719
25. García P, Alonso VL, Serra E, Escalante AM, Furlan RLE. Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry. *ACS Med Chem Lett*. Published online 2018. doi:10.1021/acsmchemlett.8b00247
26. Ramallo IA, Alonso VL, Rua F, Serra E, Furlan RLE. A Bioactive *Trypanosoma cruzi* Bromodomain Inhibitor from Chemically Engineered Extracts. *ACS Comb Sci*. Published online 2018. doi:10.1021/acscmbosci.7b00172
27. Chua MJ, Robaa D, Skinner-Adams TS, Sippl W, Andrews KT. Activity of bromodomain protein inhibitors/binders against asexual-stage *Plasmodium falciparum* parasites. *Int J Parasitol Drugs Drug Resist*. Published online 2018. doi:10.1016/j.ijpddr.2018.03.001
28. Hanquier J, Gimeno T, Jeffers V, Sullivan WJ. Evaluating the GCN5b bromodomain as a novel therapeutic target against the parasite *Toxoplasma gondii*. *Exp Parasitol*. Published online 2020. doi:10.1016/j.exppara.2020.107868
29. Brand M, Clayton J, Moroglu M, et al. Controlling Intramolecular Interactions in the Design of Selective, High-Affinity, Ligands for the CREBBP Bromodomain. *ChemRxiv*. Published online 2020. doi:10.26434/chemrxiv.12081999
30. Tallant C, Bamborough P, Chung CW, et al. Expanding Bromodomain Targeting into Neglected Parasitic Diseases. *ACS Infect Dis*. Published online 2021. doi:10.1021/acsinfectdis.1c00387
31. Alonso VL, Tavernelli LE, Pezza A, Cribb P, Ritagliati C, Serra E. Aim for the Readers!

- Bromodomains As New Targets Against Chagas' Disease. *Curr Med Chem*. Published online 2018. doi:10.2174/0929867325666181031132007
32. Ritagliati C, Villanova G V., Alonso VL, et al. Glycosomal bromodomain factor 1 from *Trypanosoma cruzi* enhances trypomastigote cell infection and intracellular amastigote growth. *Biochem J*. 2016;473(1):73-85. doi:10.1042/BJ20150986
33. Alonso VL, Villanova GV, Ritagliati C, Motta MCM, Cribb P, Serra EC. *Trypanosoma cruzi* bromodomain factor 3 binds acetylated α -tubulin and concentrates in the flagellum during metacyclogenesis. *Eukaryot Cell*. Published online 2014. doi:10.1128/EC.00341-13
34. Villanova GV, Nardelli SC, Cribb P, et al. *Trypanosoma cruzi* bromodomain factor 2 (BDF2) binds to acetylated histones and is accumulated after UV irradiation. *Int J Parasitol*. Published online 2009. doi:10.1016/j.ijpara.2008.11.013
35. Alsford S, Horn D. Cell-cycle-regulated control of VSG expression site silencing by histones and histone chaperones ASF1A and CAF-1b in *Trypanosoma brucei*. *Nucleic Acids Res*. Published online 2012. doi:10.1093/nar/gks813
36. Schulz D, Mugnier MR, Paulsen EM, et al. Bromodomain Proteins Contribute to Maintenance of Bloodstream Form Stage Identity in the African Trypanosome. *PLoS Biol*. Published online 2015. doi:10.1371/journal.pbio.1002316
37. Lander N, Li ZH, Niyogi S, Docampo R. CRISPR/Cas9-induced disruption of paraflagellar rod protein 1 and 2 genes in *Trypanosoma cruzi* reveals their role in flagellar attachment. *MBio*. Published online 2015. doi:10.1128/mBio.01012-15
38. Taylor MC, Kelly JM. pTcINDEX: A stable tetracycline-regulated expression vector for *Trypanosoma cruzi*. *BMC Biotechnol*. Published online 2006. doi:10.1186/1472-6750-6-32
39. Alonso VL, Ritagliati C, Cribb P, Serra EC. Construction of three new gateway® expression plasmids for *Trypanosoma cruzi*. *Mem Inst Oswaldo Cruz*. Published online 2014. doi:10.1590/0074-0276140238
40. Nguyen Ba AN, Pogoutse A, Provart N, Moses AM. NLStradamus: A simple Hidden Markov Model for nuclear localization signal prediction. *BMC Bioinformatics*. Published online 2009. doi:10.1186/1471-2105-10-202
41. Goos C, Dejung M, Janzen CJ, Butter F, Kramer S. The nuclear proteome of *Trypanosoma brucei*. *PLoS One*. Published online 2017. doi:10.1371/journal.pone.0181884
42. Meiler J, Baker D. ROSETTALIGAND: Protein-small molecule docking with full side-chain flexibility. *Proteins Struct Funct Genet*. Published online 2006. doi:10.1002/prot.21086
43. Alonso VL, Ritagliati C, Cribb P, Cricco JA, Serra EC. Overexpression of bromodomain factor 3 in *Trypanosoma cruzi* (Tc BDF3) affects parasite differentiation and protects it against bromodomain inhibitors. *FEBS J*. 2016;283(11):2051-2066. doi:10.1111/febs.13719
44. Lander N, Chiurillo MA, Docampo R. Genome Editing by CRISPR/Cas9: A Game Change in the Genetic Manipulation of Protists. *J Eukaryot Microbiol*. Published online 2016. doi:10.1111/jeu.12338
45. Samworth CM, Esposti MD, Lenaz G. Quenching of the intrinsic tryptophan fluorescence of mitochondrial ubiquinol—cytochrome-c reductase by the binding of ubiquinone. *Eur J Biochem*. Published online 1988. doi:10.1111/j.1432-1033.1988.tb13761.x

Supplementary Figures.

Supplementary Figure 1. Expression of *TcBDF2dm* in epimastigotes.

Supplementary Figure 2. Effect of over-expression of *TcBDF2* and *TcBDF2dm* on the epimastigote cell cycle measured by flow cytometry. Parasites overexpressing either *TcBDF2HA* or *TcBDF2dm* were subjected to flow cytometry to analyze the cell cycle progression at different times post tetracycline induction. Histograms are plotted as number of events vs. propidium iodide absorbance (PI-A).

Supplementary Figure 3. Correct folding of recombinant *Tc*BDF2 and *mTc*BDF2dm was corroborated by circular dichroism. Soluble proteins (5 mM) in 0.1 mM phosphate buffer, pH 8, were measured by circular dichroism spectroscopy using a spectropolarimeter Jasco J-810 (Easton, MD, USA).

Supplementary Figure S4: Validation of RosettaLigand scripts and correlation with dissociation constants obtained by quenching of intrinsic tryptophan fluorescence. Predictions were made by extensive sampling of the conformational space using the RosettaLigand protocol. Briefly, the three-dimensional structures of the compounds were retrieved from PubChem database and their conformers were generated using BioChemicalLibrary suit (BCL). The structure of BD2 was generated with AlphaFold2 using the sequence of *Tc*BDF2 from Dm28c strain. The starting pose of the compounds for local docking was obtained by aligning the co-crystal of BRD4 and JQ1(+) (PDB: 3MXF) with BD2 and taking the coordinates of the centroid of JQ1(+). Extensive sampling was carried out generating 7500 models for each compound, ordering them according to the interface energy calculated by Rosetta. Intermodel structural similarity was performed by calculating the ligand RMSD between each model and the lowest interface energy model. **A:** Comparison between the structure of BD2/BSP co-crystal (PDB: 6NIM) and the structures of the 5 lowest interface energy models. **B:** Funnel plot showing convergence of minimum energy models of BD2/BSP predictions in structures around 2.5 Å RMSD from the crystal structure (red circle). **C:** Box-plot comparing the energy and mean RMSD of the 5 lowest energy models for each prediction. BD2/BSP and BD2/iBET-151 displayed both the lowest median interface energy and the lowest Mean RMSD, consistent with the results obtained in vitro. **D:** Superposition of the 5 structures with the lowest interface energy for each compound. Obtaining minimum energy structures in heterogeneous poses is highly suggestive of a low affinity for the binding pocket, which is reflected in high RMSD values. **REU:** Rosetta Energy Units.